中国医药健康产业股份有限公司关于子公司收到《税务事项通知书》暨补缴税款相关事项的公告

Group 1 - Company subsidiary Hainan Tongyong Sanyang Pharmaceutical Co., Ltd. needs to pay tax arrears of approximately 21.49 million yuan and late fees of about 10.74 million yuan, while Hainan Kangli Pharmaceutical Co., Ltd. needs to pay tax arrears of approximately 21.28 million yuan and late fees of about 11.71 million yuan, totaling around 65.22 million yuan [1][2] - The tax payment does not involve any administrative penalties and will be settled as required [1] - The tax arrears and late fees will be included in the company's 2025 profit and loss, expected to impact the net profit by 65.22 million yuan [2] Group 2 - Company subsidiary Tianfang Pharmaceutical Co., Ltd. received approval for the drug Clarithromycin Tablets, which passed the consistency evaluation for generic drug quality and efficacy [4][5] - Clarithromycin is used to treat infections caused by sensitive pathogens, with a market presence since 1991 [5][8] - The total investment in the Clarithromycin project is approximately 11.79 million yuan [7] - The domestic sales of Clarithromycin in public hospitals and grassroots medical institutions were about 407 million yuan in 2024, with the company's sales at approximately 2.83 million yuan [8]